Shin Nippon Biomedical Laboratories

Basic Information

Stock Code
2395
Industry
Service Industry
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
May 1973
Listing Year
March 2004
Official Website
https://www.snbl.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Cojinbio, Linical, Transgenic Group, DNA Chip Research Institute, Ubicom, H.U. Group Holdings, Falco Holdings, BML, C&R, Migalo HD, Human Metabolome Technologies, PhoenixBio

Overview

Shin Nippon Biomedical Laboratories, founded in 1973, is a leading contract research organization (CRO) in the pharmaceutical development outsourcing industry, providing comprehensive services from basic research to clinical trials, making it Japan's largest CRO.

Current Situation

Shin Nippon Biomedical Laboratories achieved consolidated revenue of approximately ¥26.5 billion and operating profit of approximately ¥4.2 billion for the fiscal year ending March 2024, positioning it as Japan's largest basic research contract company. It has extensive track records in both non-clinical and clinical fields and is expanding globally in the US and Asia. Its strengths include proprietary intranasal delivery technology and translational research initiatives. The company actively supports pharmaceutical development through subsidiaries and invests in emerging companies to enhance competitiveness and diversify. It is also building comprehensive support systems for medical-related businesses such as Medipolis. Focusing on environmental considerations and social contributions, it aims to develop regional healthcare and the bioindustry. Moving forward, it plans sustainable growth through new technology development and overseas market expansion.

Trivia

Interesting Facts

  • Founded in 1957 as Japan's first pharmaceutical development contract organization.
  • Owns Japan's largest non-clinical testing facilities in Kagoshima.
  • Established proprietary intranasal delivery technology and obtained patents.
  • Contributed to the establishment of WAVE Life Sciences, listed on US NASDAQ.
  • Also supports the International Proton Therapy Center business.
  • Engages in diversified Medipolis business.
  • Listed on the Tokyo Stock Exchange Prime Market.
  • Provides high-precision analysis at Wakayama Drug Metabolism Analysis Center.
  • Owns animal breeding facilities in Cambodia for non-clinical testing support.
  • Handles wide range from pharmaceutical development to medical services via multiple subsidiaries.
  • Chairman and President Ryoichi Nagata has significant influence in the industry.
  • Established joint venture Shin Nippon Biomedical Laboratories PPD in 2015.
  • Classified under Nikkei industry code 071 for bio and pharmaceuticals related.
  • Actively invests in and provides technology support to biotech ventures.
  • Operates composite facilities contributing to regional healthcare and industry promotion.

Hidden Connections

  • Collaborated with Harvard University to establish WAVE Life Sciences, strengthening overseas expansion.
  • Shin Nippon Biomedical Laboratories' intranasal delivery technology utilized in new drug development by multiple pharmaceutical companies.
  • Contributes to latest medical technologies through support for Medipolis International Proton Therapy Center.
  • Cambodia animal breeding facilities serve as research support hub in Asia region.
  • Stable management structure with major holdings by Nagata family and trust banks.
  • Collaborates with SBI Group on US emerging company investment fund for overseas venture support.
  • One of Japan's few major companies providing comprehensive support for entire pharmaceutical development process.
  • Drug Metabolism Analysis Center receives high evaluations from pharmaceutical companies in Japan and abroad.

Future Outlook

Growth Drivers

  • Growth in global CRO market and international expansion
  • Increased demand from accelerated innovative pharmaceutical development
  • Adoption of cutting-edge technologies and commercialization of intranasal delivery technology
  • Expansion of Medipolis business in medical and energy fields
  • Strengthened open innovation including biotech venture investments
  • Reinforcement of business foundations in Asia and North America
  • Improved customer satisfaction through regulatory compliance expertise
  • Enhanced response to Sustainable Development Goals (SDGs)
  • Clinical trial efficiency and data quality improvement via IT utilization
  • Enhanced brand value through strengthened regional community collaborations
  • Value-added expansion through advanced analysis technology provision
  • Risk diversification via diverse business portfolio

Strategic Goals

  • Expand overseas revenue ratio to over 40%
  • Commercialize intranasal delivery technology and increase licensing income
  • Expand and diversify revenue from Medipolis-related businesses
  • Provide industry-leading clinical trial support services
  • Strengthen CSR through achievement of sustainability goals
  • Create new businesses through biotech venture investments
  • Further expand and advance cutting-edge research facilities
  • Improve development efficiency by 40% through IT infrastructure
  • Nationwide rollout of regional healthcare support programs
  • Strengthen regulatory approval support systems in multiple countries

Business Segments

Pharmaceutical Development Outsourcing (CRO)

Overview
Provides high-quality development support through integrated outsourcing from basic pharmaceutical research to clinical trials.
Competitiveness
Japan's largest non-clinical testing facilities and extensive clinical expertise
Customers
  • Domestic pharmaceutical companies
  • Foreign pharmaceutical companies
  • Biotech ventures
  • University research institutions
  • Public research institutions
Products
  • Non-clinical safety testing
  • Clinical trial planning support
  • Pharmacokinetic analysis
  • Clinical trial operations support
  • Regulatory consulting

Medipolis-Related Business

Overview
Provides diversified services through advanced medical facility operations and energy businesses.
Competitiveness
Unique business model integrating medical and energy sectors
Customers
  • Medical institutions
  • Patients
  • Energy companies
  • Local governments
Products
  • Proton therapy support
  • Geothermal power
  • Medical lodging facility operations
  • Medical research support

Biotech Venture Support and Investment Business

Overview
Investment and services supporting innovative biotech development and market deployment.
Competitiveness
Joint research track record with Harvard University and global network
Customers
  • Drug discovery ventures
  • University spin-offs
  • New business creation companies
Products
  • Research support services
  • Funding provision
  • Technology licensing

US Business Expansion

Overview
Local response and international pharmaceutical development support leveraging US bases.
Competitiveness
Rapid service provision through US local subsidiaries
Customers
  • US pharmaceutical companies
  • Biotech companies
  • Local research institutions
Products
  • Non-clinical testing services
  • Clinical trial management
  • Bioanalysis

Asia Business Expansion

Overview
Research support services in Asia including Cambodia bases.
Competitiveness
Non-clinical testing utilizing local animal breeding facilities
Customers
  • Southeast Asian pharmaceutical companies
  • Research institutions
  • Government agencies
Products
  • Animal model development
  • Drug evaluation
  • Clinical trial support

Drug Metabolism Analysis Services

Overview
Specialized analysis services for drug metabolism.
Competitiveness
Advanced technology at Wakayama Drug Metabolism Analysis Center
Customers
  • Pharmaceutical companies
  • Biotech companies
  • Academia
Products
  • Pharmacokinetic analysis
  • Metabolite identification
  • Bioanalytical technology

Clinical Trial Implementation Support Services

Overview
Comprehensive support for clinical trial execution to enable efficient operations.
Competitiveness
Extensive clinical trial track record and specialized staff
Customers
  • Pharmaceutical companies
  • Medical institutions
  • Clinical trial outsourcing organizations
Products
  • Clinical trial coordination
  • Patient recruitment support
  • Clinical trial safety management

Medical Information Management Services

Overview
IT services supporting efficient use of medical and trial data.
Competitiveness
Provision of integrated platforms
Customers
  • Medical institutions
  • Pharmaceutical companies
  • Research institutions
Products
  • Data management systems
  • Information analysis
  • Electronic medical records integration

Renewable Energy Business

Overview
Provision of clean energy aimed at reducing environmental impact.
Competitiveness
Energy management linked to medical facilities
Customers
  • Local communities
  • Facility operators
Products
  • Geothermal power
  • Biomass utilization

University Spin-Off Support

Overview
Comprehensive services from technology transfer to commercialization.
Competitiveness
Synergy creation through domestic and international networks
Customers
  • Universities
  • Researcher ventures
Products
  • R&D support
  • Financial assistance
  • Technology integration

Global Licensing Negotiation Support

Overview
International business support including IP and licensing contracts.
Competitiveness
Specialized team with extensive international experience
Customers
  • Pharmaceutical companies
  • Biotech companies
Products
  • Contract negotiations
  • IP management
  • Business strategy consulting

Drug Discovery Screening Services

Overview
Supports efficient drug discovery for new drug candidate compounds.
Competitiveness
State-of-the-art equipment and specialized technology
Customers
  • Pharmaceutical companies
  • Biotech labs
Products
  • High-throughput screening
  • Novel drug discovery
  • Compound library provision

Competitive Advantage

Strengths

  • Japan's largest non-clinical research facilities
  • Extensive clinical trial track record and advanced expertise
  • International competitiveness through global expansion
  • Proprietary intranasal delivery technology development
  • Diversified medical-related business expansion
  • Strong R&D support network
  • Business synergies from diverse subsidiaries
  • High-specialty drug metabolism analysis technology
  • Long-term trust and track record in the industry
  • Active biotech venture investment activities
  • Regional medical and energy businesses
  • High-quality safety testing management
  • First in Japan to establish US local subsidiary
  • Convenience of integrated outsourcing services
  • Strengthened collaboration with cutting-edge technologies

Competitive Advantages

  • Holds top share in Japan for non-clinical testing facilities, gaining high trust
  • Rapid global response through bases in the US and Asia
  • Strengthens bridging from basic to clinical via translational research
  • Leads new pharmaceutical development with proprietary intranasal delivery technology
  • Provides comprehensive pharmaceutical development support via diverse subsidiaries
  • Balances safety and efficiency with extensive clinical trial support and specialized staff
  • Unique market position integrating regional energy and medical businesses
  • Advances technological innovation through partnerships with university spin-offs
  • Improves clinical research quality with high-precision drug metabolism analysis
  • Builds brand value in overseas markets as a Japan-origin CRO
  • Achieves customer time and cost reductions through comprehensive services
  • Applies healthcare facility operation know-how to other businesses
  • Realizes data management efficiency with advanced IT systems
  • High new business creation potential through diversified investments
  • Ensures reliability with strict regulatory compliance capabilities

Threats

  • Increased costs from further strengthening of pharmaceutical regulations
  • Price competition from intensifying domestic and international CRO rivals
  • Decline in competitiveness from delays in new technology adoption
  • Business environment fluctuations due to global economic uncertainty
  • Shortage of specialized technicians from intensifying talent competition
  • Increased IP-related risks
  • Stagnation of clinical trials due to emerging infectious diseases
  • Impact of exchange rate fluctuations on revenue
  • Challenges in overseas facility operations due to geopolitical risks
  • Business failure risks from investee ventures
  • Damage to research facilities from natural disasters
  • Decline in social credibility from delays in sustainability responses

Innovations

2023: Made Satsuma US subsidiary consolidated

Overview
Strengthened investment and business collaboration with emerging biotech ventures in North America.
Impact
Accelerated global business expansion and technology diversification.

2022: Made Inaresearch Co., Ltd. consolidated subsidiary

Overview
Incorporated specialized pharmaceutical evaluation and analysis company into the group.
Impact
Significantly improved quality of contract business through enhanced analysis capabilities.

2021: Advanced intranasal delivery technology

Overview
Achieved improved drug delivery efficiency through proprietary technology enhancements.
Impact
Increased effectiveness in supporting new therapeutic drug development.

2020: Expanded Medipolis Ibusuki geothermal power

Overview
Expanded renewable energy business utilizing local resources.
Impact
Successfully reduced environmental impact and secured stable revenue sources.

2024: Advanced IT systems for clinical trial operations

Overview
Introduced latest cloud technology to streamline clinical trial data management.
Impact
Achieved cost reductions and improved data quality.

2023: Introduced drug discovery screening technology

Overview
Accelerated new drug discovery with high-throughput screening equipment.
Impact
Shortened development periods and increased number of candidate compounds.

2022: Launched biotech venture support program

Overview
Systematized support for technology commercialization of university spin-offs.
Impact
Strengthened collaborations with promising future companies and improved investment returns.

2021: Advanced Drug Metabolism Analysis Center

Overview
Improved analysis precision with latest analytical equipment.
Impact
Contributed to higher accuracy in clinical trials.

2020: Started joint research on new intranasal drug development

Overview
Initiated basic research in collaboration with domestic and international universities.
Impact
Suggests potential for expanded drug efficacy.

2024: Strengthened clinical trial patient recruitment support

Overview
Built online matching platform.
Impact
Shortened clinical trial start times and improved patient satisfaction.

Sustainability

  • Promotion of renewable energy use
  • Waste reduction and recycling enhancement
  • Expansion of regional healthcare support activities
  • Environmentally considerate research operations
  • Promotion of diversity and inclusion
  • Strengthened employee health management programs
  • Environmental technology development with biotech ventures
  • Expansion of clean energy business
  • Environmental education activities in collaboration with local governments
  • Compliance adherence and information security enhancement
  • ISO14001 certification and continuous improvement
  • Formulation and disclosure of environmental impact reduction targets